AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02710396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2 (programmed cell death (PD) proteins).~Pembrolizumab 200 mg will be administered IV every 3 weeks.
Study NCT02710396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve (AUC)) = 5 IV on day 1 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
Study NCT02710396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m2 IV on days 1, 8 and 15 every 3 weeks administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
Study NCT02710396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV administered for 2 cycles concurrently with cycles 1 and 2 of pembrolizumab.
Study NCT00000308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: 15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
Study NCT00000308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-amphetamine
Description: 15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
Study NCT00000308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT02980497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Zero Mouthwash (without alcohol)
Description: 20 ml of rinse for 30 seconds, twice a day
Study NCT02980497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Listerine Antiseptic Mouthwash (with alcohol)
Description: 20 ml of rinse for 30 seconds, twice a day
Study NCT02875054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint induced movement therapy (CIMT)
Description: Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
Study NCT02875054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand-arm bimanual intensive training (HABIT)
Description: Facilitates the translation of gains to improve goal-directed bimanual performance.
Study NCT02060123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qigong training
Description: a total of 103 hours over a period of 5.5 months, consisting of:~* Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),~* Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and~* Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours).
Study NCT02060123 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control- Health talks
Description: Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
Study NCT02324257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I, and QW, Q3W, or as a combined QW/Q3W step up dosing regimen (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
Study NCT02324257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
Study NCT02773303 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mente Autism™
Description: A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
Study NCT02773303 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
Study NCT02324257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as an IV infusion as necessary to treat adverse events.
Study NCT02151240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foscarnet Sodium
Study NCT02151240 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Study NCT01194804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
Study NCT04229472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High density electrophysiological mapping
Description: Recording of electrophysiological data using a high density contact catheter during pacing at the time of catheter ablation for atrial fibrillation.
Study NCT04229472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance Imaging
Description: Late gadolinium enhance cardiac magnetic resonance imaging (in AcQMap group only)
Study NCT00151125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11
Description: 25 mcg/kg subcutaneously daily for seven days
Study NCT00151125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11
Description: 50 mcg/kg subcutaneously daily for 7 days
Study NCT00151125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-11
Description: 10 mcg/kg subcutaneously daily for 7 days
Study NCT02077985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Adapted Dental Environment
Description: See study arm description.
Study NCT00479024 — intervention group
Intervention type: DRUG
Intervention: iodinated contrast agent
Description: iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
Study NCT02969850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D Supplementation
Description: Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
Study NCT02969850 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this group will receive a placebo.
Study NCT02969850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
Study NCT02969850 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium
Description: If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
Study NCT01892319 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician
Study NCT01892319 — intervention group
Intervention type: DRUG
Intervention: other injectable antidiabetic treatment regimens
Description: Patients will be treated according to routine clinical practice at the discretion of the treating physician
Study NCT01260363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
Study NCT01528020 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
Study NCT04811885 — intervention group
Intervention type: OTHER
Intervention: The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
Description: The Effects of Covid 19 Pandemic on the Cardiovascular Heath of Children With Autism Spectrum Disorder
Study NCT05210335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist's recommendation to physicians about drug related problems
Description: Clinical pharmacist's recommendation to physicians about drug related problems
Study NCT01260363 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia
Description: Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
Study NCT01702662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photopill treatment
Description: 2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
Study NCT03904524 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET-to-Meet
Description: The overall objective of this study is to pilot test, in advance of a larger randomized trial, a scalable, nurse-led intervention to ensure timely interdisciplinary family meetings are held on behalf of critically-ill ICU patients who cannot participate in discussions about their care.
Study NCT03032081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: High intensity exercise, defined as an exercise intensity of > 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
Study NCT03032081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity exercise
Description: Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
Study NCT02974387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorometholone(FML)
Study NCT02974387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol (Lotemax)
Study NCT01955850 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for insomnia
Description: Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
Study NCT04171648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Roasted Peanut Treatment
Description: The subjects will consume 2 ounces or \~48 grams of roasted in shell peanuts a day for two weeks.
Study NCT04171648 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boiled Peanut Treatment
Description: The subjects will consume 2 ounces or \~48 grams of boiled peanuts a day for two weeks.
Study NCT02946541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evogliptin 5mg
Description: evogliptin 5mg, QD
Study NCT02946541 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, QD
Study NCT01797965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB019 (Daclizumab)
Description: Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
Study NCT01705197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avanafil 100 or 200mg
Description: This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
Study NCT01705197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avanafil 100 or 200mg
Description: This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
Study NCT03265639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: P-inulin
Study NCT00860483 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: observational
Description: PET Scan
Study NCT03556735 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment with PEMF equipment
Description: Treatment with PEMF in 8 weeks
Study NCT05800106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate capsules generic product
Description: Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
Study NCT05800106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib malate capsules reference product
Description: Sunitinib is an inhibitor targeting multiple receptor tyrosine kinases (RTK).
Study NCT02695524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapula-focused exercises
Study NCT02695524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapula-focused exercises
Study NCT02695524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Study NCT03484351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fall Monty Activity Programme (FallMAP)
Description: The programme delivered during this feasibility study will consist of a total of 12 multifactorial falls prevention group exercise sessions of 90-100 minutes in duration, followed by a 20-30 minute social activity. The sessions will be offered over a period of 8 weeks. Each session will comprise (a mix of) seven program components of the intervention: 1) falls prevention education, 2) FaME group-based exercises for strength and dynamic balance, 3) (Preparing for) home exercises, 4) Interactive, virtual reality gamefied exercises, 5) Getting on and off the floor / floorwork / safe landing \& falls technique activities, 6) Home falls hazard evaluation and 7) A social activity after the exercise session.
Study NCT01881971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: suger pill manufactured to mimic crestor pills
Study NCT00976456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab + Pemetrexed
Description: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
Study NCT01881971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rouvastatin calcium
Study NCT00976456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab + Pemetrexed + Carboplatin
Description: Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
Study NCT01528020 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual and Group Supportive Therapy
Description: The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
Study NCT02283450 — intervention group
Intervention type: DRUG
Intervention: Qiliqiangxin Capsule
Study NCT01613950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
Study NCT01613950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
Study NCT03367325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDS-NVAF
Description: The CDS-NVAF is intended for patients diagnosed with NVAF and treated with VKA. This tool calculates the time in the therapeutic range (TTR) using the Rosendaal method considering the last International Normalized Ratio (INR) data. The INR data are found in the clinical history of NVAF patients. The CDS-NVAF will be activated when the physician introduces the last INR value. At this time the TTR will be calculated automatically. If the TTR value is \< 65%, a pop up screen with a warning text will open suggesting a change to DOAC therapy. The physician can decide whether to change or not the previous prescription. If the TTR value in > 65% the pop up screen will not appear. The TTR value will remain registered on the screen of the follow up of oral anticoagulant use and can be consulted in future queries. The diffusion of the CDS-NVAF will be made by an announcement on the first day of the intervention when the health care professional opens the electronic clinical history.
Study NCT02407171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: 200 mg every 2 weeks by IV infusion
Study NCT02407171 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
Study NCT04741906 — intervention group
Intervention type: PROCEDURE
Intervention: Dental implant surgery
Description: Dental surgery in patients treated with antiresorptive medication
Study NCT04741906 — intervention group
Intervention type: PROCEDURE
Intervention: Prosthetic treatment
Description: Prosthetic treatment and loading of the dental implants
Study NCT02417467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine E-Cigarette
Study NCT02417467 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-Nicotine E-Cigarette
Study NCT02417467 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Study NCT02417467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Study NCT01743872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Injection
Description: Media #1: IV Contrast (Omnipaque 350) will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml) Intervention protocol will be followed per Cross-Reference Intervention.
Study NCT01743872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextran Injection
Description: Media #2: Dextran 40 Solution will be continuously injected at a rate range of 2.5-6ml/s for a maximum of 5 seconds. (Volume range of 12.5- 30ml. Intervention protocol will be followed per Cross-Reference Intervention.
Study NCT01743872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 Injection
Description: Media #3: Carbon Dioxide (CO2) will be injected with large volume hand injection syringe as per the usual protocol. This be done with particular attention to avoid air in the closed system. In addition to supine, there is also an option that the patient's distal limb may be elevated to improve the flow of CO2 during injection. The surgeon will also wait at least 2 minutes between each CO2 injection to allow any potentially trapped CO2 to dissolve. A range of 20-60 ml will be used with each hand injection based on the data from the initial 5-10 pilot patients. Intervention protocol will be followed per Cross-Reference Intervention.
Study NCT01743872 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heparinized Normal Saline Injection
Description: Media #4: Heparinized Normal Saline (Heparin NS) will be hand injected using 20 mL (2 U/mL) in antegrade fashion.